What's new? Log in Free sign up

Satellos Bioscience (MSCLF)

Company Profile

Company profile

Ticker

MSCLF, MSCL

Exchange

Website

CEO

Mr. Francis Gleeson B.B.A. M.B.A

Incorporated

Canada (Federal)

Location

Ontario, Canada

Sector

Health Technology > Biotechnology

Former names

ICO THERAPEUTICS INC

SEC CIK

MSCLF stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

$25.02 mm in equity / options / securities to be acquired, sold $25.02 mm, 13 investors

$33.29 mm in equity / options / securities to be acquired, sold $33.29 mm, 16 investors

$2.1M in equity / options / securities to be acquired, sold $99.16K, 1 investor

$2.51M in equity / options / securities to be acquired, sold $188K, 1 investor

$971.69K in equity / options / securities to be acquired, sold $151.83K, 1 investor

$7.93M in equity / options / securities to be acquired, sold $2.03M, 2 investors

$125.91K in equity, sold $125.91K, 1 investor

$50.37K in equity, sold $50.37K, 1 investor

$3.3M in equity, sold $3.3M, 5 investors

$2.71M in equity, sold $2.71M, 2 investors

Latest ownership filings

No filings

Press releases

From Benzinga Pro

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

- Satellos plans to highlight Phase 1 safety and PK data for SAT-3247 Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

- Company remains on track to report Phase 1a data from both the Single- and Multiple-Ascending Dose (SAD and MAD) cohorts in the healthy volunteer portion of the study in 1Q 2025 at an upcoming major medical

Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders,

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.